Davita Inc vs Tyson Foods, Inc. — how do they compare? Davita Inc trades at $181 (market cap $11.38B), while Tyson Foods, Inc. trades at $56.08 (market cap $19.85B). The key difference: Tyson Foods, Inc. is the larger of the two by market cap, and Tyson Foods, Inc. pays a 3.62% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | TSN | |
|---|---|---|
Market Cap | $11.38B | $19.85B |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $68.75 |
52-Week Low | $103.87 | $50.72 |
Enterprise Value | $24.10B | $27.12B |
Dividend Yield | — | 3.62% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $181.72, down 1.07% on the day, with technical indicators showing a mixed but overall bullish signal. The stock has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $4.02 surpassing estimates. Revenue growth is steady, reaching $13.64B in 2025, though net income margin has fluctuated. Analyst sentiment is cautiously optimistic with a consensus price target of $232.25, representing significant upside potential from current levels.
The outlook for DVA is positive, driven by strong volume growth and strategic execution, but faces risks from reimbursement pressures and a high debt load. Investment opportunity lies in the valuation discount to analyst targets and consistent earnings beats, while key risks include payer mix challenges and macroeconomic factors affecting healthcare spending.
Tyson Foods (TSN) trades at $55.97, down 2.08% on the day, amid a bearish technical signal and mixed quarterly performance. Recent Q3 2026 earnings of $0.99 per share beat estimates, but revenue and volumes declined year-over-year. The company maintains a strong cash flow from operations of $2.16B in 2025, though net income margins are thin at 1.03%. Analyst consensus is a Buy with a $68.50 price target, highlighting a potential 22% upside from current levels.
The outlook for TSN is cautiously optimistic, with valuation metrics like P/S of 0.36 and EV/EBITDA of 10.38 suggesting potential undervaluation. Key risks include persistent losses in the beef segment due to high cattle costs and competitive pressures. Investment opportunity lies in the strength of chicken and prepared foods divisions, supported by a stable dividend yield. Monitoring Q3 2026 earnings release and beef margin normalization is critical for future performance.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →